Annotated Text of Current Rule
April 14, 2015

Proposed Regulated Drug Rule

1.0 Authority

This rule is established under the authority of 18 V.S.A. §§ 4201 and 4202 which authorizes the Vermont Board of Health to designate regulated drugs for the protection of public health and safety.

2.0 Purpose

This rule designates drugs and other chemical substances that are illegal or judged to be potentially fatal or harmful for human consumption unless prescribed and dispensed by a professional licensed to prescribe or dispense them. The rule also restricts the possession of certain drugs above a specified quantity.

3.0 Definitions

3.1 "Analog" means one of a group of chemical components similar in structure but different with respect to elemental composition. It can differ in one or more atoms, functional groups or substructures, which are replaced with other atoms, groups or substructures.

3.2 "Benchmark Unlawful Dosage" means the quantity of a drug commonly consumed over a twenty-four hour period for any therapeutic purpose, as established by the manufacturer of the drug. Benchmark Unlawful dosage is not a medical or pharmacologic concept with any implication for medical practice. Instead, it is a legal concept established only for 18 V.S.A. § 4234.

3.3 "Depressant drug" means any drug which contains any substances, its salt, optical isomers, salts of its optical isomers, derivatives or analogs of substances, designated in Section 5.0 of this rule as habit forming because of its effect on the central nervous system or as having a serious potential for abuse arising out of its effect on the central nervous system.

3.4 "Derivative**"** shall mean a compound that can be obtained from a parent compound as a result of a chemical reaction which replaces one atom/functional group with a different one.

3.5 "Hallucinogenic Drug" means stramonium, mescaline or peyote, lysergic acid diethylamide, and psilocybin, and all synthetic equivalents of chemicals contained in resinous extractives of Cannabis sativa, or any salts

or derivatives or compounds of any preparations or mixtures thereof, and any other substance which is designated as habit-forming or as having a serious potential for abuse arising out of its effect on the central nervous system or its hallucinogenic effect in the regulations adopted by the Board of Health under 18 V.S.A.§ 4202.

3.6 "Narcotic drug" means opium, coca leaves, pethidine (isonipecaine, meperidine), and opiates or their compound, manufacture, salt, alkaloid, or derivative, and every substance neither chemically nor physically distinguishable from them, and preparations containing such drugs or their derivatives, by whatever trade name identified and whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis or by a combination of extraction and chemical synthesis, as the same are so designated in the regulations adopted by the Board of Health under 18 V.S.A.§ 4202.

3.7 "Regulated drug" means a narcotic drug, a depressant or stimulant drug, other than methamphetamine, a hallucinogenic drug, Ecstasy, marijuana, or methamphetamine whose possession or use is regulated by law.

3.8 "Stimulant drug" means any drug which contains any quality of a substance, its salt, optical isomers, salts of it optical isomers, derivatives or analogs of substances, designated in Section 4.0 of this rule as habit forming because of its effect on the central nervous system or as having a serious potential for abuse arising out of its effect on the central nervous system.

~~**REGULATED DRUGS RULE**~~
~~VERMONT HEALTH REGULATIONS~~

~~I. Definitions~~

~~**A. Analog** shall mean one of a group of chemical compounds similar in structure but different with respect to elemental composition. It can differ in one or more atoms, functional groups or substructures, which are replaced with other atoms, groups, or substructures.~~

~~**B. Derivative** shall mean a compound that can be obtained from a parent compound as a result of a chemical reaction which replaces one atom/functional group with a different one.~~

~~**II. Regulated Drugs:**~~

~~Pursuant to the provisions of 18 VSA 4201-4202 (as amended) the Vermont Board of Health hereby designates regulated drugs for purposes of Chapter 84, Title 18 Vermont Statutes Annotated as follows:~~

~~**A. Depressant and stimulant drugs; Trade or Chemical Name**~~

~~A stimulant drug is any drug which contains any quantity of a substance, its salt, optical isomers, salts of its optical isomers, derivatives or analogs of substances, designated below as habit forming because of its effect on the central nervous system or as having a serious potential for abuse ar~~

4.0 Stimulant Drugs; Trade or Chemical Name

- 2-AI; 2-Aminoindane
- 2-diphenylmethylpyrrolidine; 2-benzylhydrylpyrrolidine; OR (S)-(-)-2-(diphenylmethyl)pyrrolidine; OR (S)-2-diphenylmethylpyrrolidine; OR (2S)-2-benzylhydrylpyrrolidine; OR (2S)diphenylmethylpyrrolidine
- 2-DPMP; desoxypipradrol; OR diphenylprolinol; OR 2-diphenylmethylpiperidine
- 2-FMA; 2-fluoromethamphetamine
- 2-FMC; 2-fluoromethcathinone
- 2-methylmethcathinone; 2-MMC;2-Methyl MC
- 3-FMC; 3-fluoromethcathinone
- 3,4-DMMC; 3,4-dimethylmethcathinone
- 3, 4 methylenedioxy-methamphetamine (MDMA)
- 3,4-methylenedioxy-N-methylcathinone (methylone)
- 3,4-methylenedioxypyrovalerone (MPDV)
- 4-bromomethcathinone; 4-BMC
- 4-chloromethcathinone;4-CMC;Clephedrone
- 4-EMC; 4-ethylmethcathinone; OR 4-ethyl-methcathinone
- 4FA, PFA; 4-fluoroamphetamine; parafluoroamphetamine
- 4-FMA; 4-fluoromethamphetamine

- 4-FMC, Flephedrone; 4-fluoromethcathinone
- 4-FPP, pFPP; 4-fluorophenylpiperazine
- 4-MBC, Benzedrone; (±)-1-(4-methylphenyl)-2-(benzylamino)propan-1-one; OR 4-methyl- N-benzylcathinone; OR N-benzyl-4-methylcathinone; OR 1-(4-methylphenyl)-2- benzyla-minopropan-1-one
- 4-MEC; 4-methyl-N-ethylcathinone; OR 4-methylethcathinone; OR para-methyl-N-ethylcathinone; OR para-methylethcathinone; OR 4-methyl-ethylcathinone
- 4-MPD; 4-Methyl-Pentedrone
- 5-IAI; 5-Iodo-2-Aminoindane
- 5-ME, 5-methyl-ethylone
- a-ethylaminopentiophenone
- a-PBP, alpha-PBP; alpha-Pyrrolidinobutiophenone; OR a-Pyrrolidinobutiophenone; OR (RS)1-phenyl-2-(1-pyrrolidinyl)-1-pentanone
- a-PPP, alpha-PPP; alpha-pyrrolidinopropiophenone; OR a-pyrrolidinopropiophenone
- a-PVP, alpha-PVP; alpha-Pyrrolidinopentiophenone; OR a-Pyrrolidinopentiophenone; OR 1- phenyl-2-(1-pyrrolidinyl)-1-pentanone; OR alpha-pyrrolidinovalerophenone; OR a- pyrrolidinovalerophenone
- Amphetamine
- Benzphetamine
- bk-2C-B; bk-4 Bromo-2,5-dimethoxyphenethylamine
- BZP; benzylpiperazine; OR N-benzylpiperazine
- Buphedrone; a-methylamino-butyrophenone; OR 2-(methylamino)-1-phenylbutan-1-one; OR alpha-methylamino-butyrophenone
- Butylone, bk-MBDB; beta-Keto-N-methylbenzodioxolylpropylamine; OR beta-Keto-N- methyl-3,4-benzodioxyolybutanamine
- Cathine
- Cathinone
- Cathinone derivatives: Any compound (not being bupropion) structurally derived from 2-amino-1-phenyl-1-propanone by modification in any of the following ways: (i) by substitution in the phenyl ring to any extent with alkyl, alkoxy, alkylenedioxy, haloalkyl or halide substituents, whether or not further substituted in the phenyl ring by one or more other univalent substituents; (ii) by substitution at the 3-position with an

alkyl substituent; (iii) by substitution at the nitrogen atom with alkyl or dialkyl groups, or by inclusion of the nitrogen atom in a cyclic structure.

- Chlorphentermine
- Clortermine
- D2PM; diphenyl-2-pyrrolidinyl-methanol ; diphenyl prolinol
- DBP; DBZP; 1,4-dibenzylpiperazine
- Diethylpropion
- Dimethocaine; (3-diethylamino-2,2-dimethylpropyl)-4-aminobenzoate
- Ethcathinone; 2-ethylamino-1-phenyl-propan-1-one
- Ethylone; 3,4-methylenedioxy-N-ethylcathinone; OR 3,4-methylenedioxyethylcathinone; OR 3,4-methylenedioxy-ethylcathinone; OR 3,4-methylenedioxyethcathinone
- Eutylone; beta-Keto-Ethylbenziodioxolylbutanamine HMMC; 3-methoxymethcathinone; 3-MeOMC
- M11; dimethylone
- MaPPP, 4-MePPP; 4-methyl-alpha-pyrrolidinopropiophenone; OR 4-methyl-a-pyrrolidinopropiophenone; OR methylpyrrolidinopropiophenone
- MBPV; 5-DBFPN; 1-(2,3-dihydrobenzofuran-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one
- MBZP; 1-methyl-4-benzylpiperazine
- mCPP; 1-(3-chlorophenyl)piperazine
- MDAI; methylenedioxy-aminoindane; OR 5,6-methylenedioxy-2-aminoindane
- MDAT; 6,7-methylenedioxy-2-aminotetralin
- MDPBP; 3,4-methylenedioxy-alpha-pyrrolidinobutiophenone; OR 3,4-methylenedioxy-a- pyrrolidinobutiophenone
- MDPPP; 3,4-methylenedioxy-a-pyrrolidinopropiophenone; OR (RS)-1-(3,4-methylenedioxyphenyl)-2-(1-pyrrolidinyl)-1-propanone; OR 3,4-methylenedioxy-alpha-pyrrolidinopropiophenone
- MeOPP; 1-(4-methoxyphenyl)piperazine
- MOPPP; 4-methoxy-alpha-pyrrolidinopropiophenone; OR 4-methoxy-a-pyrrolidinopropiophenone

- MPBP; 4-methyl-alpha-pyrrolidinobutyrophenone; OR 4-methyl-a-pyrrolidinobutryophenone; OR 4-methyl-alpha-pyrrolidinobutiophenone; OR 4-methyl-a-pyrrolidinobutiophenone; 4-MPBP

- Mazindol

- Mephedrone (4-methyl methtramadolcathinone)

- Mephtetramine; MTA

- Methamphetamine

- Methcathinone

- Metamfepramone; N,N-dimethylcathinone

- Methedrone, Bk-PMMA, PMMC; para-methoxymethcathinone; OR 4-methoxymethcathinone; OR methoxyphedrine; OR (RS)-1-(4-methoxyphenyl)-2-(methylamino)propan-1-one

- Methylphenidate

- MT-45; IC-6; NSC 299236; 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine

- NRG-1; Naphyrone, naphthylpyrovalerone;

- NRG-2

- NM2AI; NM-2AI; N-Methyl-2-Aminoindane

- Pemoline (including organometallic complexes and chelates thereof)

- Pentedrone; a-methylamino-Valerophenone; OR 2-(methylamino)-1-phenyl-1-pentanone; OR 2-methylamino-1-phenyl-1-pentanone

- Pentylone; beta-Keto-N-methylbenzodioxolylpentanamine; OR beta-keto-ethylbenzodioxolylpentanamine

- Phendimetrazine

- Phenmetrazine

- Phentermine

- Pyrovalerone; (Valerophenone, Thymergix, Centroton)

- TFMPP; 1-[3-(trifluoromethyl)phenyl]piperazine

~~(i) ising out of its effect on the central nervous system:~~

~~(ii) A depressant drug is any drug which contains any substance, its salt, optical isomers, salts of its optical isomers, derivatives or analogs of substances, designated below as habit forming because of its effect on the central nervous system or as having a serious potential for abuse arising out of its effect on the central nervous system:~~

5.0 Depressant Drugs; Trade or Chemical Name

- Alprazolam
- Barbituric acid and its derivatives
- Chloral beteine
- Chloral Hydrate
- Chlorexadol
- Clonazepam
- Clorazepate
- Clordiazepoxide
- Diazepam
- Ethchlorvynol
- Ethinamate
- Fenfluramine
- Flurazepam
- Glutethimide
- Ketamine
- Lorazepam
- Lysergic acid
- Lysergic acid amide
- Mebutamate
- Mecloqualone
- Meprobamate

- Methaqualone
- Methyprylon
- Oxazepam
- Paraldehyde
- Petrichloral
- Phenazepam; BD 98; Fenazepam
- Phencyclidine
- Sulfondiethylmethane
- Sulfonethylmethane
- Sulfonmethane
- Temazepam
- Triazolam

6.0 Narcotic Drugs; Trade or Chemical Name

~~**A. Narcotic, Narcotics and Narcotic Drugs; Trade or Chemical Name**~~

~~Narcotic, narcotics, or narcotic drugs mean any substance hereafter designated, its salts, isomers, salts of isomers, derivatives or analogs, whenever the existence of such salts, isomers, salts of isomers, derivatives or analogs are possible within the specific chemical designation:~~

- 7-hydroxymitragynine; (α*E*,2*S*,3*S*,7a*S*,12b*S*)-3-Ethyl-1,2,3,4,6,7,7a,12b-octahydro-7a- hydroxy-8-methoxy-α-(methoxymethylene)indolo[2,3-a]quinolizine-2-acetic acid methyl ester
- AH-7921; 3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide
- Acetorphine
- Acetyldihydrocodeine
- Acetyl-fentanyl
- Acetylmethadol

- Allylprodine
- Alphacetylmethadol
- Alphameprodine
- Alphamethadol
- Alphaprodine
- Anileridine
- Benzethidine
- Benzylmorphine
- Betacetylmethadol
- Betameprodine
- Betamethadol
- Betaprodine
- Bezitramide
- Buprenorphine
- Clonitazene
- Coca leaves and any salt, compound derivative, or preparation of coca leaves, and any salt compound derivative or preparation thereof which is chemically equivalent or identical regardless of optical Isomers with any of these substances, except that the substances shall not include decocainized coca leaves or extraction of coca leaves, which extractions do not contain cocaine or ecognine
- Cocaine
- Codeine
- Codeine methylbromide
- Codeine-N-Oxide
- Cyprenorphine
- Desomorphine
- Dextromoramide

- Dextrorphan
- Diampromide
- Diethylthiambutene
- Difenoxin
- Dihydrocodeine
- Dihydromorphine
- Dimenoxadol
- Dimepheptanol
- Dimethylthiambutene
- Dioxaphetyl butyrate
- Diphenoxylate
- Dipipanone
- Drotebanol
- Ethylmethylthiambutene
- Ethylmorphine
- Etonitazene
- Etorphine
- Etoxeridine
- Fentanyl
- Furethidine
- Heroin
- Hydrocodone
- Hydromorphinol
- Hydromorphone
- Hydroxypethidine
- Isomethadone

- Ketobemidone
- Levomethorphan
- Levomoramide
- Levophenacylmorphan
- Levorphanol
- Metazocine
- Methadone
- Methadone-Intermediate 4-cyano-2-dimethylamino-4, 4-dipehnyl butane
- Methiopropamine, MPA
- Methyldesorphine
- Methyldihydromorphine
- Methopholine; 1-[2-(4-chlorophenyl)ethyl]-6,7-dimethoxy-2-methyl-1,2,3,4 tetrahydroisoquinoline
- Metopon
- Moramide-Intermediate, 2- methyl-3-morpholino-1, 1-diphenylpropane-carboxylic acid
- Morpheridine
- Morphine
- Morphine methylbromide
- Morphine methylsulfonate
- Morphine-N-Oxide
- Myrophine
- Nicocodeine
- Nicomorphine
- Noracymethadol
- Norlevorphanol

- Normethadone
- Normorphine
- Norpipanone
- ~~Nortilidine; ethyl (1R, 2S)2(methylamino)1-phenylcyclohex-3-ene-1-carboxylate~~
- o-desmethyltramadol; 3-[2-(1-Amino-1-methylethyl)-1-hydroxycyclohexyl]phenol
- Opium poppy and poppy straw
- Raw opium
- Opium extracts
- Oxycodone
- Oxymorphone
- Pentazocine (Hcl and ASA)
- Pethidine
- Pethidine-Intermediate- A, 4-cyano-1-methyl-4-phenylpiperdine
- Pethidine-Intermediate-B,ethyl-4-phenylpiperidine-4-carboxylate
- Pethidine-Intermediate-C,1-methyl-4-phenylpiperidine-4-carboxylic acid
- Phenadoxone
- Phenampromide
- Phenazocine
- Phenomorphan
- Phenoperidine
- Pholcodine
- Piminodine
- Piritramide
- Proheptazine
- Properidine
- Propiram

- Propoxyphene
- Racemethorphan
- Racemoramide
- Racemorphan
- Thebacon
- Thebaine
- Tilidine
- Tramadol
- Trimeperidine
- Viminol;1-[1-(2-chlorobenzyl)- 1*H*-pyrrol-2-yl]- 2-(di-*sec*-butylamino) ethanol

Any compound specified in 18 VSA 4215 a(b) shall be excluded for purposes of this regulation.

~~C. **7.0 Hallucinogenic Drugs; Synthetic Cannabinoids, Tryptamines, Cannabimimetics, Mescaline Analogs, Dissociatives; Trade or Chemical Name**~~

~~A hallucinogenic drug is any drug which contains any quantity of substance designated below as being habit forming or as having a serious potential for abuse arising out of its effect on the central nervous system or as having a hallucinogenic effect, or its salts, isomers, salts of isomers, derivatives or analogs, whenever the existence of such salts, isomers, salts of isomers, derivatives or analogs is possible within the specific chemical designation:~~

7.0 Hallucinogenic Drugs; Synthetic Cannabinoids; Tryptamines; Cannabinimimetics; Mescaline Analogs; Dissociatives; Trade or Chemical Name.

- 1-(4-methoxybenzoyl)-4-methylpiperazine;MEXP;Methoxypiperamide
- 2,5-dimethoxyamphetamine; 2,5-dimethoxy-a-methylphenethylamin 2,5 DMA
- 2-MeO-ketamine; methoxyketamine

- 2C-B; 4-bromo-2,5-dimethoxy-benzeneethanamine, monohydrochloride
- 2C-C; 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine
- 2C-D; 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine
- 2C-E; 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine
- 2C-H; 2-(2,5-Dimethoxyphenyl)ethanamine
- 2C-I; 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine
- 2C-N; 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine
- 2C-P; 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine
- 2C-T-2; 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine
- 2C-T-4; 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine
- 2C-T-7; 2,5-dimethoxy-4-(propylthio)-benzeneethanamine, monohydrochloride
- 2C-TFM-NBOMe; 2-(4-trifluoromethyl-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
- ~~2C-X~~
- 2CBCB-NBOMe; N-(2-methoxybenzyl)-1-[(7R)-3-bromo-2,5-dimethoxybicyclo[4.2.0]octa- 1,3,5-trien-7-yl]methanamine
- 2CBFly-NBOMe; N-(2-Methoxybenzyl)-1-(8-bromo-2,3,6,7-tetrahydrobenzo[1,2-b:4,5- b']difuran-4-yl)-2-aminoethane
- 3,4,5-trimethoxy amphetamine
- 3,4-methylenedioxy amphetamine
- 3-HO-PCE; 3-[1-(ethylamino)cyclohexyl]phenol
- 3-HO-PCP
- 3-Methoxyphencyclidine; 3-MeO-PCP; 1-[1-(3-methoxyphenyl)cyclohexyl]-piperidine
- 4-AcO-DET; 3-(2-Diethylaminoethyl)-1H-indol-4-yl acetate
- 4-AcO-DMT; 3-[2-(Dimethylamino)ethyl]-1H-indol-4-yl acetate
- 4-AcO-DPT
- 4-AcO-MET; 3-(2-Ethyl(methyl)aminoethyl)-1H-indol-4-yl acetate

- 4-bromo-2, 5-dimethoxyamphetamine; DOB; bromo-DMA
- 4-HO-MET; 3-(2-(ethyl(methyl)amino)ethyl)-1H-indol-4-ol
- 4-HO-MIPT; 3-(2-[Isopropyl(methyl)amino]ethyl)-1H-indol-4-ol; 4-hydroxy-MIPT
- 4-HO-MPMI; (R)-3-(N-methylpyrrolidin-2-ylmethyl)-4-hydoxyindole
- 4-HO-MPT; 3-{2-[methyl(propyl)amino]ethyl}-1H-indol-4-ol
- 4-MeO-AET
- 4-MeO-MIPT
- 4-MeO-PCP; 1-[1-(4-methoxyphenyl)cyclohexyl]-piperidine; 4-Methoxyphencyclidine (methoxydine)
- 4-methoxyamphetamine; 4-methoxy-a-methylphenethylamine paramethoxyamphetamine: PMA
- 4-methyl-2, 5-dimethoxyamphetamine; 4-methyl-2, 5-dimethoxy-a-ethylphenethylamine; "DOM"; and "STP."
- 4-methyl-AET
- 5-APB; 5-(2-aminopropyl)benzofuran
- 5-EAPB; 5-(2-Ethylaminopropyl)Benzofuran
- 5F-AMB; 5-fluoro AMP
- 5F-ADBICA; 5-fluoro ADBICA; N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide
- 5F-AKB48; AKB48 N-(5-fluoropentyl) analog; 5f-APINACA; APINACA 5-fluoropentyl analog; N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide
- 5F-MN-018;5-fluoro MN-18; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide
- 5F-MN24; 5-fluoro NNEI; 1-(5-fluoropentyl)-N-(naphthalen-1-yl)-1H-indole-3-carboxamide
- 5F-SDB-005; naphthalen-1-yl 1-(5-fluoropentyl)-1H-indazole-3-carboxylate
- 5F-THJ-2201; (1-(5-fluoropentyl)-1H-indazol-3-yl)(naphthalen-1-yl)methanone
- 5FAB-FUBINACA

- 5FAB-PINACA; AB-PINACA 5 fluoro analog; (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide

- 5FPB22; 5-fluoro PB-22; 5-fluoro QUPIC; 1-(5-fluoropentyl)-8-quinolinyl ester-1H-indole-3-carboxylic acid

- 5FSDB-006; 5-fluoro SDB-006; N-benzyl-1-(5-fluoropentyl)-1H-indole-3-carboxamide

- 5-IT; 5-(2-aminopropyl)indole

- 5-MAPB; 5-(2-Methylaminopropyl) Benzofuran

- 5-MeO-AMT; 1-(5-methoxy-1H-indol-3-yl)propan-2-amine

- 5-MeO-DALT; N-ally1-N-[2-(5-methoxy-1H-indol-3-yl)ethyl]prop-2-en-1-amine; 5-MED

- 5-MeO-DET; N,N-Dethyl-5-Methoxytryptamine

- 5-MeO-DIPT; 3-[2-(Diisopropylamino)ethyl]-5-methoxyindole

- 5-MeO-DMT; 2-(5-methoxy-1H-indol-3-yl)-N,N-dimethylethanamine

- 5-MeO-DPT; N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-propylpropan-1-amine

- 5-MeO-MDA; 5-methoxy-3, 4-methylenedioxy amphetamine

- 5-MeO-MIPT; N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-methylpropan-2-amine

- 5-methoxy-3,4-methylenedioxy amphetamine

- 5-MeO-MPMI; (R)-3-(N-methylpyrrolidin-2-ylmethyl)-5-methoxyindole

- 5F-UR-144; (5-fluoropentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone; XLR11

- 6-APB; 6-(2-aminopropyl)benzofuran

- 7-hydroxymitragynine; (αE,2S,3S,7aS,12bS)-3-Ethyl-1,2,3,4,6,7,7a,12b-octahydro-7a-hydroxy-8-methoxy-α-(methoxymethylene)indolo[2,3-a]quinolizine-2-acetic acid methyl ester

- 25B-NBOMe; NBOMe-2C-B; BOM 2-CB; Cimbi-36; 2-(4-bromo-2,5-dimethoxyphenyl)-N- [(2-methoxyphenyl)methyl]ethanamine

- 25C-NBOMe ; 2C-C-NBOMe; NBOMe-2C-C; Cimbi-82; 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine

- 25I-NBF; 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-fluorophenyl)methyl]ethanamine

- 25I-NBMD; NBMD-2C-I; Cimbi-29; 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2,3-methylenedioxyphenyl)methyl]ethanamine

- 25I-NBOH; 2-((2-(4-iodo-2,5-dimethoxyphenyl)ethylamino)methyl)phenol

- 25I-NBOMe; 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine

- A1 dodeca-2E, 4E, 8Z, 10Z – tetraenoic acid isobutyl amide

- A2 dodeca-2E, 4E, dienoic acid idobutylamide

- A796,260; 1-(2-morpholin-4-ylethyl)-1H-indol-3-yl]-(2,2,3,3 tetramethylcyclopropyl) methanone

- A-834,735; 1-(tetrahydropyran-4-ylmethyl)-1H-indol-3-yl]-(2,2,3,3-tetramethylcyclopropyl)methanone

- A-836,339; N-[3-(2-methoxyethyl)-4,5-dimethyl-1,3-thiazol-2-ylidene]-2,2,3,3-tetramethylcyclopropane-1-carboxamide

- AB-001; 1-pentyl-3-(1-adamantoyl) indole

- AB-034; [1-[(N-methylpiperidin-2-yl)methyl]-1H-indole-3-yl]-(2,2,3,3-tetramethylcyclopropyl)methanone

- AB-CHMINACA; N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide

- AB-PINACA

- ACEA; N-(2-chloroethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide

- ACPA; N-cyclopropyl-5Z,8Z,11Z,14Z-eicosatetraenamide

- ADBICA; N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-carboxamide

- AH-7921; 3,4-dichloro-N-[(1dimethylamino)cyclohexylmethyl]benzamide

- AKB-48; N-adamantyl-1-pentylindazole-3-carboxamide (APINACA)

- AL-LAD; 6-allyl-6-nor-LSD; 6-Allyl-6-nor-lysergic acid diethylamide

- AM630; Iodopravadoline; [6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)-methanone

- AM-679; 1-pentyl-3-(2-iodobenzoyl)indole

- AM-694; 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole; OR 1-[(5-fluoropentyl)-1H-indol-3- yl]-(2-iodophenyl)methanone

- AM-1220; (R)-(1-((1-methylpiperidin-2-yl)methyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone; OR 1-((N-methylpiperidin-2-yl)methyl)-3-(1-naphthoyl)indole; OR 1-[(N-methylpiperidin-2-yl)methyl]-3-(1-naphthoyl)indole

- AM-1241; 1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole

- AM-1248; 1-[(N-methylpiperidin-2-yl)methyl]-3-(adamant-1-oyl)indole

- AM-2201; 1-(5-fluoropentyl)-3-(1-naphthoyl)indole

- AM-2233; 1-[(N-methylpiperidin-2-yl)methyl]-3-(2-iodobenzoyl)indole

- AM-4113

- AMT; a-methyltryptamine

- ASDB-FUB-187 BAY 38-7271; (-)-(R)-3-(2-Hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluorobutyl-1- sulfonate

- Bufotenine; 3-(b-dimethylaminoethyl) 5-hydroxyindole; 3-(2-di-methylamineothyl) -5-indolol;N, N-dimethylserotonin; 5-hydroxy-N-dimethyltryptamine; mappine.

- CB-13, SAB-378; Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone

- CP47,497

- CP 47,497 homologues; Known as the C6, C7, C8 or C9 homologues and also the dimethylhexyl, dimethylheptyl; dimethyloctyl or dimethylnonyl homologues

- CP 50,556-1, Levonantradol; 9-hydroxy-6-methyl-3-[5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl]acetate; OR [(6S,6aR,9R, 10aR)-9-hydroxy-6-methyl-3-[(2R)-5-ph enylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl] acetate; OR [9-hydroxy-6-methyl-3-[5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10, 10a-octahydrophenanthridin-1-yl]acetate

- CP 55,940; 2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl) cyclohexyl]-5-(2-methyloctan-2-yl)phenol

- cannabicyclohexanol

- Cannabimimetic Agents means, collectively, any chemical that is a cannabinoid receptor type 1 (CB1) or cannabinoid receptor type 2 (CB2) agonist, or any salts, isomers, derivatives, or analogs of these chemicals. Structural classes include but are not limited to: (a) 2-(3-hydroxycyclohexyl)phenol with substitution at the 5-position of the phenolic ring by alkyl or alkenyl, whether or not substituted on the cyclohexyl ring to any extent. (b) 3-(1-naphthoyl)indole or 3-(1-naphthyl)indole with substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent, whether or not substituted on the naphthoyl or naphthyl ring to any extent. (c) 3-(1-naphthoyl)pyrrole with substitution at the nitrogen atom of the pyrrole ring, whether or not further substituted in the pyrrole ring to any extent, whether or not substituted on the naphthoyl ring to any extent. (d) 1-(1-naphthylmethyl)indene with substitution of the 3-position of the indene ring, whether or not further substituted in

the indene ring to any extent, whether or not substituted on the naphthyl ring to any extent.(e) 3-phenylacetylindole or 3-benzoylindole with substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the phenyl ring to any extent. (f) indole- (2,2,3,3-tetramethylcyclopropyl)methanone, with substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the phenyl ring to any extent. (g) N- adamantyl-indole-3-carboxamide, with substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the phenyl ring to any extent. (h) (1,3-thiazol-2- ylidine)-2,2,3,3- tetramethylcyclopropane-1-carboxamide, with substitution to any extent at any position of the thiazolylidine ring.

- DET; Diethyltryptamine; N, N-Diethyltryptamine
- DIPT; Diisopropyltryptamine
- DMT; Dimethyltryptamine
- DPT; N,N,-dipropyltryptamine
- Dichloropane, RTI-111, O-401; methyl (1R,2S,3S,5S)-3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]octane-2-carboxylate
- EAM-2201; JWH-210 N-(5 fluoropentyl) analog; (4-ethyl-1-naphthalenyl)[1-(5-fluoropentyl)-1H-indol-3-yl]-methanone
- EG-018; naphthalen-1-yl(9-pentyl-9H-carbazol-3-yl)methanone
- Ethyl-ketamine; 2-(2-chlorophenyl)-2-(ethylamino)cyclohexanone
- FDU-PB-22; naphthalen-1-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate
- FAB-144; (1-(5-fluoropentyl)-1H-indazol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone
- F-UPB-22
- FUB-AKB48; AKB48 N-(4-fluorobenzyl) analog; N-((3s,5s,7s)-adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide
- FUB-PB22; FUB-PB-22; ; quinolin-8-yl-1-(4-fluorobenzyl)-1H-indole-3-carboxylate
- FUBIMINA; AM2201 Benzimidazole analog; BIM-2201, FTHJ; (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl)(naphthalen-1-yl)methanone
- HDMP-28; Methylnaphthidate
- HU-210; (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3- (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c] chromen-1-ol; OR [(6aR,10aR)-9-(hy droxymethyl)-6,6-dimethyl-3-(2-methyl octan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol; OR 1,1-Dimethylheptyl-11-hydroxytetrahydrocannabinol

- HU-211, Dexanabinol; (6aS, 10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)- 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol; OR (6aS, 10aS)-9-(hydroxymethyl)- 6,6-dimethyl- 3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol

- HU-243; 3-dimethylheptyl-11-hydroxyhexahydrocannabinol; canbisol, nabidrox

- HU-308; [(91R,2R,5R)-2-[2,6-dimethoxy-4-(2-methyloctan-2-yl)phenyl]-7,7-dimethyl-4- bicyclo[3.1.1]hept-3-enyl]methanol

- HU-331; 3-hydroxy-2-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl- 2,5-cyclohexadiene-1,4-dione

- Ibogaine; 7-Ethyl-6, 6a,7,8,9,10,12, 3-octahydro-2-methoxy-6, 9-methano-5H-pyrido (1', 2': 1,2 azepine 4, 5-b) indole; tab ernanthe iboga

- JTE-907; N-(benzol[1,3]dioxol-5-ylmethyl)-7-methoxy-2-oxo-8-pentyloxy-1,2-dihydroquinoline-3-carboxamide

- JWH-007; 1-pentyl-2-methyl-3-(1-naphthoyl)indole

- JWH-015; (2-methyl-1-propyl-1H-indol-3-yl)-1-naphthalenylmethanone; OR 1-propyl-2- methyl-3-(1-naphthoyl)indole; OR (2-methyl-1-propyl-1H-indol-3-yl)-1-naphthalenyl-methanone

- JWH-016; (1-butyl-2-methyl-1H-indol-3-yl)-1-naphthalenyl-methanone)

- JWH-018; AM-678; Naphthalen-1-yl-(1-pentylindol-3-yl)methanone

- JWH-019; napthanlen-1-yl-(1-pentylindol-3-yl)methanone; OR 1-hexyl-3-(1-naphthoyl)indole; OR 1-hexyl-3-(naphthoyl)indole; OR 1-hexyl-3-(naphthalen-1-oyl)indole

- JWH-022; 1-naphthalenyl[1-(4-penten-1-yl)-1H-indol-3-yl]-methanone

- JWH-030; naphthalen-1-yl-(1-pentylpyrrol- 3-yl)methanone

- JWH-073; naphthalen-1-yl-(1-butylindol-3-yl)methanone

- JWH-081; 4-methoxynapthalen-1-yl-(1-pentylindol-3-yl)methanone; OR 1-pentyl-3-(4- methoxy-1-naphthoyl)indole; OR 4-methoxynaphthalen-1-yl-(1-pentylindole-3-yl) methanone; OR 1-pentyl-3-[1-(4-methoxynaphthoy)]indole

- JWH-098; 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole; OR 4-methoxynaphthalen- 1-yl-(1-pentyl-2-methylindol-3-yl)methanone

- JWH-122; 1-pentyl-3-(4-methyl-1-naphthoyl)indole; OR (4-methyl-1-naphthalenyl)(1-pentyl-1H-indol-3-yl)-methanone

- JWH-147; (1-hexyl-5-phenyl-1H-pyrrol-3-yl)-1-naphthalenyl-methanone

- JWH-164; 1-pentyl-3-(7-methoxy-1-naphthoyl)indole; OR 7-methoxynaphthalen-1-yl-(1- pentylindol-3-yl)methanone
- JWH-167; 1-pentyl-3-(phenylacetyl)indole
- JWH-175; 3-(napthalen-1-ylmethyl)-1-pentyl-1H-indole; OR 1-Pentyl-1H-indol-3-yl-(1- naphthyl)methane
- JWH-176; E-1-[1-(1-Naphthalenylmethylene)-1H-inden-3-yl]pentane
- JWH-184; 1-Pentyl-1H-indol-3-yl-(4-methyl-1-naphthyl)methane
- JWH-199
- JWH-200; WIN 55,225; (1-(2-morpholin-4-ylethyl)indol-3-yl)-naphthalen-1-ylmethanone
- JWH-201; 1-pentyl-3-(4-methocyphenylacetyl)indole; OR 1-pentyl-3-(4-methoxyphenylacetyl)indole
- JWH-203; 2-(2-chlorophenyl)-1-(1-pentylindol-3-yl)ethanone; OR 1-pentyl-3-(2-chlorophenylacetyl)indole
- JWH-210; 4-ethylnaphthalen-1-yl-(1-pentylindol-3-yl)methanone; OR 1-pentyl-3-(4-ethyl-1- naphthoyl)indole
- JWH-250; 2-(2-methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone; OR 1-pentyl-3-(2-methoxyphenylacetyl)indole; OR 1-pentyl-3-(methoxyphenylacetyl)indole; OR 1-(1-pentyl-1H-indol-3-yl)-2-(2-methoxyphenyl)-ethanone
- JWH-251; 2-(2-methylphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone; OR 1-pentyl-3-(2-methylphenylacetyl)indole
- JWH-302; 2-(3-methoxyphenyl)-1-(1-pentyl-1H-indol-3-yl)-ethanone
- JWH-307; (5-(2-fluorophenyl)-1-pent ylpyrrol-3-yl)-naphthalen-1-ylmethanone
- JWH-370; [5-(2-methylphenyl)-1-pentyl-1H-pyrrol-3-yl]-1-naphthalenyl-methanone
- JWH-398; 1-pentyl-3-(4-chloro-1-naphthoyl)indole
- L-759,633; 3-(1,1-dimethylheptyl)-6aR,7,10,10aR-tetrahydro-1-methoxy-6,6,9-trimethyl-6H-dibenzo[b,d]pyran
- L-759,656
- Lysergic acid
- Lysergic acid amide
- Lysergic acid dimethylamide

- LSZ; Lysergic acid 2,4-dimethylazetidide, Diazedine, Lambda, LA-SS-AzLysergic acid diethylamide
- MAM-2201; 4-methyl-1-naphthalenyl(1-fluoropentyl-1H-indol-3-yl)methanone
- MIPT; N-isopropyl-N-methyltryptamine
- MA-CHMINICA; AMB N-METHYLCYCLOHEXYL ANALOG, AB-CHMINACA, MAB-AB-CHMINACA; methyl (1-(cyclohexylmethyl)-1H-indazole-3-carbonyl)-L-valinate
- MDMB-CHMINICA; (S)-MDMB-CHMINACA; N-[[1-(cyclohexylmethyl)-1H-indazol-3-yl]carbonyl]-3-methyl-L-valine, methyl ester
- Mepirapim; JWH-018-4(methylpiperazine); (4-methylpiperazin-1-yl)(1-pentyl-1H-indol-3-yl)methanone, monohydrochloride
- Mescaline
- Methoxetamine (MXE); 3-MeO-2-Oxo-PCE; (RS)2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone
- ~~Methylergonovine~~
- MMB-2201; I-AMB; methyl (1-(5-fluoropentyl)-1H-indole-3-carbonyl)-L-valinate
- MMB-CHMINACA; (2S)-methyl-2-(1-(cyclohexylmethyl)-1 H-indol-3-ylcarbonylamino)-3,3-dimethylbutanoate
- MN-18; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide
- MN-24; NNEI; N-1-naphthalenyl-1-pentyl-1H-indole-3-carboxamide; AM-6527
- Mitragynine
- N-ethyl-3 piperidyl benzilate
- N-methyl-3-piperidyl benzilate
- NM2201
- Peyote
- Psilocybin
- Psilocin; 4-OH-DMT
- RCS-4, SR-19; [(4-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone]; OR 1-pentyl-3-[(4- methoxy)-benzoyl]indole; OR 1-pentyl-3-(4-methoxybenzoyl)indole; OR (4-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone

- RCS-8, SR-18; 1-(2-(2-cyclohexylethyl)-1H-indol-3-yl)-2-(2-methyoxyphenylethanone); OR 1-[2-(2-cyclohexylethyl)-1H-indol-3-yl]-2-methoxyphenylethanone; OR 1-(2- cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole

- STS-135; N-adamantyl-1-pentylindazole-3-carboxamide

- Salvia divinorum

- Salvinorin A, Active ingredient of salvia plant

- SDB-005; naphthalen-1-yl 1-pentyl-1H-indazole-3-carboxylate

- SR 144528; 5-(4-chloro-3-methylphenyl)-1-[(4-methylphenyl)methyl]-N-[(1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]hept-2-yl]-1H-pyrazole-3-carboxamide

- STS-144; (1-(5-fluoropentyl)-1H-indol-3-yl)(pyridin-3-yl)methanone

- Stramonium

- THJ-018; JWH-018 Indazole analog; 1-naphthalenyl(1-pentyl-1H-indazol-3-yl)-methanone

- THJ-2201; Fluoropentyl JWH-018 Indazole, AM2201 indazole analog, 5-Fluoro

- Tetrahydrocannabinols (Since nomenclature of these substances is not internationally standardized, compounds of these structures, regardless of numeric designation of atomic position are covered).

- Thiophene Analog of Phencyclidine; 1-[1-(2-thlenyl) cyclohexyl] piperidine; 2-Thyneyl Analog of Phencyclidine; TPCP

- UR-144; (1-Pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone

- URB-597; [3-(3-carbamoylphenyl)phenyl]-N-cyclohexylcarbamate

- URB-602; Cyclohexyl [1,1'-biphenyl]-3-ylcarbamate

- URB-754; 6-methyl-2-[(4-methylphenyl)amino]-4H-3,1-benzoxazin-4-one

- URB-937; 3'-carbamoyl-6-hydroxy-[1,1'-biphenyl]-3-yl cyclohexylcarbamate

- Viminol;1-[1-(2-chlorobenzyl)- 1H-pyrrol-2-yl]- 2-(di-sec-butylamino) ethanol

- W-15; (E)-4-chloro-N-(1-phenethylpiperidin-2-ylidene)benzenesulfonamide

- WIN 48,098, Pravadoline; (4-Methoxyphenyl)-[2-methy l-1-(2-(4-morpholinyl)ethyl)indol-3- yl]methanone; OR (4-methoxyphenyl)-[2-methyl-1-(2-morpholin-4-ylethyl)indol-3- yl]methanone

- WIN 55,212-2; (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]- 1,4-benzoxazin-6-yl]-1-napthalenylmethanone; OR [2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[(1,2,3-de)-1,4-benzoxazin-6-yl]-1-napthalenylmethanone

8.0 Exemptions

~~III.~~ **8.1** **Paregoric** (camphorated opium tincture) is specifically exempted from this regulation.

~~IV.~~ **8.2** **Exempt Substances.** The following substances when labeled and in the form and quantity listed in the following section of 21 Code of Federal Regulations, Chapter II, Part 1308, dated April 1, 1976 and the Federal Register are hereby exempted from this regulation:

- 21 CFR 1308.22
- 21 CFR 1308.24(i)
- 21 CFR 1308.32(b)
- 41 FR 14190 & 14189
- 41 FR 16552 – 16553
- 41 FR 21346
- 41 FR 28515 – 28516
- 41 FR 14189 – 14190
- 41 FR 16552 – 16553
- 41 FR 28515 – 28516

~~**III. Severability.** If any part of this regulation, or the application thereof to any person, persons or circumstances, shall be held invalid, the remainder of this regulation and application to a person, persons or circumstances other than those as to which it is held invalid, shall not be affected thereby.~~

~~**IV. Repealer.** Section 3 of existing Health Regulations, Part III, Chapter 1, are hereby repealed.~~

9.0 Dosages and Doses

~~(a)~~ 9.1 ~~Preface~~ 18 V.S.A. § 4234 directs the Board of Health to establish a

Benchmark Unlawful Dosage for selected stimulants, depressants, and narcotic drugs. The Board of Health has done so, but wishes to formally preface this submission with an explanation of these dosages. The **Benchmark Unlawful Dosage** is not a medical or pharmacologic concept with any implication for medical practice. Instead, it is a legal concept established only for this statute.

In clinical practice, there is no one recommended dose and no predetermined maximum dose for most drugs. Most drugs have more than one legitimate use, and doses vary accordingly. The Board of Health does not intend to guide or restrict medical practice in any way. These doses do not represent a standard of practice.

With these principles in mind, the Board of Health defines the **Benchmark Unlawful Dosage** as the quantity of drug commonly consumed over a twenty-four hour period for any therapeutic purpose, as established by the manufacturer of the drug.

~~**(b)**~~ **9.2 Benchmark Unlawful Dosage**

The following ~~"~~benchmark unlawful dosages~~"~~ are established for the drugs named:

Drug	Dosage
• Hydrocodone	45mg
• Codeine	360mg
• Hydromorphone	24mg
• Alprazolam	4mg
• Methylphenidate	60mg
• Methadone	80mg
• Phenobarbital	260mg
• Chlordiazepoxide	100mg
• Butalbital	300mg
• Phentermine	37.5mg

- Flurazepam 30mg
- Pentobarbital 80mg
- Oxycodone 20mg
- Propoxyphene 390mg
- Morphine 180mg
- Chlorazepate 90mg
- Secobarbital 100mg
- Amylbarbital 100mg
- Phenmetrazine 75mg
- Lorazepam 10mg
- Meperidine (Pethidine) 600mg
- Pentazocine 100mg
- Dihydrocodeinone 20mg
- Temazepam 30mg
- Triazolam 0.5mg
- Opium extracts 240mg
- Tincture of opium 120mg
- Methamphetamine 25mg
- Phencyclidine 10mg
- Amphetamine 30mg
- Methaqualone (Qualludes) 500mg
- Methaqualone Hydrochloride (Parest) 500mg
- Diazepam (Valium) 40mg

- Diethypropione (Tenuate, Tepanil) 75mg